| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development | 3,555 | 5,161 | 7,124 | 14,346 |
| General and administrative | 4,022 | 4,010 | 5,104 | 4,468 |
| Total operating expenses | 7,577 | 9,171 | 12,228 | 18,814 |
| Loss from operations | -7,577 | -9,171 | -12,228 | -18,814 |
| Change in fair value of convertible notes | 0 | 0 | - | - |
| Other income | 188 | -318 | 1,197 | 1,219 |
| Total other income | 188 | -318 | 1,197 | 1,219 |
| Loss before loss from equity method investment | -7,389 | -9,489 | -11,031 | -17,595 |
| Provision for income taxes | - | 0 | - | - |
| Loss from equity method investment | 0 | 0 | - | - |
| Net loss | -7,389 | -9,489 | -11,031 | -17,595 |
| Net loss per share - basic | -0.6 | -0.78 | -0.9 | -1.46 |
| Net loss per share - diluted | -0.6 | -0.78 | -0.9 | -1.46 |
| Weighted average number of shares outstanding, basic | 12,240,542 | 12,197,615 | 12,197,615 | 12,076,412 |
| Weighted average number of shares outstanding, diluted | 12,240,542 | 12,197,615 | 12,197,615 | 12,076,412 |
Q32 Bio Inc. (QTTB)
Q32 Bio Inc. (QTTB)